CYAD-01, an autologous NKG2D-based CART-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK) : haematological cohorts of the dose escalation segment of a phase 1 trial

Sallman, DA; Kerre, T; Havelange, V; Poiré, X; Lewalle, P; Wang, ES; Brayer, JB; Davila, ML; Moors, I; Machiels, JP; Awada, A; Alcantar-Orozco, EM; Borissova, R; Braun, N; Dheur, MS; Gilham, DE; Lonez, C; Lehmann, FF; Flament, A

Sallman, DA (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.

LANCET HAEMATOLOGY, 2023; 10 (3): E191

Abstract

Background CYAD-01 is an autologous chimeric antigen receptor (CAR) T-cell product based on the natural killer (NK) group 2D (NKG2D) receptor, which b......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索